Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace
PayPal (NASDAQ: PYPL)
Digital Transactions with Substantial Upside
PayPal Holdings, Inc. (PYPL) has earned a commanding spotlight, boasting an impressive 13% rise in its stock price over the last five days alone. This surge stems from explosive second-quarter financial results that crushed Wall Street expectations.
Financial Results That Impress
PayPal reported an EPS of $1.19, far exceeding the forecasted 99 cents. Meanwhile, revenues hit $7.90 billion, beating the estimated $7.80 billion. This robust financial performance demonstrates PayPal’s strong operational footing even in competitive markets.
Volume Growth Fuels Position
PayPal revealed an 11% increase in total payment volumes, reaching $416.80 billion, and transaction dollars increasing 8% to $3.60 billion. These upticks highlight rising user engagement and growing transaction rates, foundational elements for sustained growth.
Source: Tada Images / Shutterstock.com
Innovations Pave the Way
The company’s latest innovations, such as faster checkout experiences and AI-generated recommendations, are helping to keep the platform fresh and engaging. These advancements position PayPal as a leader among digital payments, creating sticky user experiences that drive repeat usage.
Future Guidance on the Upswing
Looking ahead, PayPal expects mid-single-digit revenue growth and high-single-digit earnings growth for Q3. With expectations recalibrated positively, the stock appears ready to gain further momentum.
PayPal’s stock had a challenging year, declining 22% over the last twelve months. Now, with new catalysts in play and stronger-than-expected financials, it seems the worst may be behind PayPal, presenting a prime buying opportunity.
Analyst Ratings Overview for PayPal
Analysts have a positive outlook on PayPal, with a consensus rating of Overweight. The average price target of $134.41 suggests a potential gain of 14.1% from the current price.
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $134.41 |
| Potential Gain | 14.1% |
| Number of Ratings | 34 |
Sources:
Yahoo Finance,
TipRanks,
CNN Business
Legendary investor Eric Fry has been right about a lot of stock picks. With 41 recommendations increasing over 1,000% and another 20 more than 500%, his track record speaks for itself.
Click here to download his surprise list for free
and find out which companies are set to win big in 2024.
Walt Disney Co. (NYSE: DIS)
Record-Breaking Box Office
Walt Disney Co. (DIS) has been on a roll this summer with the successful release of blockbuster films, translating into a bullish outlook for investors.
Record-Breaking Box Office
Disney’s new film “Deadpool & Wolverine” took home nearly $450 million globally during its opening weekend, setting a new record for R-rated movies. But the hits didn’t stop there. “Inside Out 2” amassed a colossal $1.5 billion at the box office, becoming the highest-grossing animated movie of all time.
Source: chrisdorney / Shutterstock
More Successes on the Horizon
With more “Avengers” films in the pipeline, the internet buzz around Disney is palpable. This continued string of hits offers a much-needed lifeline to Disney’s broader entertainment empire, which had been wavering in the post-pandemic period.
Stock Presenting a Buy-the-Dip Opportunity
Despite these box office successes, DIS stock has only risen 3.5% year-to-date. This underperformance relative to the company’s blockbuster results presents a fantastic buy-the-dip opportunity for investors keen on snagging a piece of a rebounding media giant. Given the low current valuation, Disney stands out as a top stock to buy right now.
Analyst Ratings Overview for Disney
Analysts have a bullish outlook on Disney, with a consensus rating of Overweight. The average price target of $154.19 suggests a potential gain of 14.1% from the current price.
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $154.19 |
| Potential Gain | 14.1% |
| Number of Ratings | 25 |
Sources:
Refinitiv,
Bloomberg,
Yahoo Finance,
CNBC,
TipRanks
British Petroleum (NYSE: BP)
Energizing Returns for Shareholders
British Petroleum (BP) is proving to be a powerhouse in the energy sector with a recent series of shareholder-friendly moves and robust financial results.
Dividend Increase and Share Buybacks
BP recently announced a 10% raise in its quarterly dividend, hiking it up to 8 cents per share and pushing the dividend yield above 5%. Along with this, the company plans to continue its $1.75 billion share buyback program into Q3.
Source: FotograFFF / Shutterstock.com
Strong Earnings Trajectory
The company reported a Q2 profit of $2.8 billion, beating the anticipated $2.6 billion. This robust performance builds on their prior quarter’s profit of $2.7 billion and outpaces the $2.6 billion earned a year ago. These strong financials were boosted by strategic cost-cutting measures, including a hiring freeze and halting renewable energy projects to focus on high-margin core operations.
Attractive Valuation
BP’s stock is relatively flat on the year and is trading at just 10 times future earnings estimates. This makes BP an appealing choice for investors looking to grab undervalued assets with strong potential for future growth.
Analyst Ratings Overview for British Petroleum
Analysts have a positive outlook on BP, with a consensus rating of Overweight. The average price target of $34.41 suggests a potential gain of 14.1% from the current price.
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $34.41 |
| Potential Gain | 14.1% |
| Number of Ratings | 24 |
Sources:
Refinitiv,
Bloomberg,
Yahoo Finance,
CNN Business,
TipRanks
Pfizer (NYSE: PFE)
Pharma Giant’s Strong Q2 Performance
U.S. pharmaceutical giant Pfizer Inc. (PFE) continues to showcase resilience and adaptability, stepping up its game with a stellar second-quarter financial report.
Earnings Beat Expectations
Pfizer crushed Wall Street analysts’ expectations with an EPS of 60 cents, topping the predicted 46 cents. The company also outperformed on revenue, bringing in $13.28 billion against the forecasted $12.96 billion.
Source: photobyphm / Shutterstock.com
Strategic Initiatives Driving Growth
While sales only rose 2%, it marked Pfizer’s first sales increase since the end of 2022, driven by improved sales of the Covid-19 antiviral pill, Paxlovid, and other non-Covid medications. The results also highlight the effectiveness of ongoing cost-cutting initiatives aimed at delivering $4 billion in savings by the close of 2024.
Upgraded Guidance
Bolstered by strong Q2 performance, Pfizer raised its earnings guidance to a range of $2.45 to $2.65 per share for the year. Revenue expectations were also lifted to between $59.50 billion and $62.50 billion, up from the earlier forecast of $58.50 billion to $61.50 billion. The stronger forward guidance indicates a promising trajectory.
Yield and Momentum
Pfizer’s quarterly dividend yield of 5.50% and a stock price up 3% this year make it a stable choice for dividends and growth-sensitive investors alike.
Analyst Ratings Overview for Pfizer
Analysts have a positive outlook on Pfizer, with a consensus rating of Overweight. The average price target of $44.41 suggests a potential gain of 12.1% from the current price.
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $44.41 |
| Potential Gain | 12.1% |
| Number of Ratings | 19 |
Sources:
Refinitiv,
Bloomberg,
TipRanks,
Yahoo Finance
Apple (NASDAQ: AAPL)
Unveiling the Future of Consumer Electronics
Apple Inc. (AAPL), the tech behemoth, continues to captivate investors and consumers alike, thanks to its introduction of cutting-edge AI features for the next generation of iPhones.
Innovations Galore
Apple has unveiled a suite of AI enhancements, including a smarter Siri, automated email and image generation, improved photo searches, and movie creation capabilities. These features are setting up the iPhone 15, and subsequent models, for what analysts predict will be a monumental upgrade cycle.
Source: sylv1rob1 / Shutterstock
The Future is AI
Further AI capabilities are in the pipeline, such as Emoji generation, automated photo clean-up, and incorporating OpenAI’s ChatGPT, all of which will only be available on newer iPhone models. This ensures that Apple stays ahead of the curve in consumer tech innovation.
Stock Performance
Riding a wave of innovation and product upgrades, Apple’s stock is up nearly 20% this year. As Apple maintains its position at the forefront of tech advancements, it remains a compelling buy for growth-oriented investors.
Analyst Ratings Overview for Apple
Analysts are overwhelmingly bullish on Apple, with a consensus “Overweight” (Buy) rating. The average price target of $175.41 implies a potential gain of 14.1% from the current price.
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $175.41 |
| Potential Gain | 14.1% |
| Number of Ratings | 34 |
Sources:
Yahoo Finance,
TipRanks,
Refinitiv
Novo Nordisk (NYSE: NVO)
Healthcare Horizons and Market Leadership
Novo Nordisk A/S (NVO) continues its upward trajectory, driven by groundbreaking developments in its healthcare offerings, notably the multifunctionality of its drug Wegovy.
Expanding Approvals
Novo Nordisk recently received E.U. approval for its weight loss drug Wegovy to treat heart conditions. The medication has proven to reduce the risk of major cardiovascular events by 20% in clinical trials. The U.K. has also greenlighted Wegovy for treating heart conditions, expanding its therapeutic reach.
Source: joreks / Shutterstock.com
New Markets and Research Success
Adding to its accolades, Wegovy was approved in China for weight loss treatment, tapping into a market of 1.4 billion people. Furthermore, a new study suggests that another Novo Nordisk drug may slow Alzheimer